KR102782655B1 - 당단백질을 만들기 위한 세포 배양 과정 - Google Patents

당단백질을 만들기 위한 세포 배양 과정 Download PDF

Info

Publication number
KR102782655B1
KR102782655B1 KR1020247012715A KR20247012715A KR102782655B1 KR 102782655 B1 KR102782655 B1 KR 102782655B1 KR 1020247012715 A KR1020247012715 A KR 1020247012715A KR 20247012715 A KR20247012715 A KR 20247012715A KR 102782655 B1 KR102782655 B1 KR 102782655B1
Authority
KR
South Korea
Prior art keywords
antibody
ornithine
protein
mol
putrescine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247012715A
Other languages
English (en)
Korean (ko)
Other versions
KR20240055885A (ko
Inventor
존 첸
숀 로렌스
에이미 존슨
데오도어 로니
라빈드라 판굴레
타-춘 황
스콧 카버
베른하르트 쉴링
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020257008109A priority Critical patent/KR20250041082A/ko
Publication of KR20240055885A publication Critical patent/KR20240055885A/ko
Application granted granted Critical
Publication of KR102782655B1 publication Critical patent/KR102782655B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247012715A 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정 Active KR102782655B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257008109A KR20250041082A (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762529471P 2017-07-06 2017-07-06
US62/529,471 2017-07-06
US201862625744P 2018-02-02 2018-02-02
US62/625,744 2018-02-02
KR1020207000732A KR102659791B1 (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정
PCT/US2018/040734 WO2019010191A1 (en) 2017-07-06 2018-07-03 CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207000732A Division KR102659791B1 (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257008109A Division KR20250041082A (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정

Publications (2)

Publication Number Publication Date
KR20240055885A KR20240055885A (ko) 2024-04-29
KR102782655B1 true KR102782655B1 (ko) 2025-03-14

Family

ID=64904487

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247012715A Active KR102782655B1 (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정
KR1020257008109A Pending KR20250041082A (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정
KR1020217020548A Ceased KR20210084695A (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정
KR1020207000732A Active KR102659791B1 (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257008109A Pending KR20250041082A (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정
KR1020217020548A Ceased KR20210084695A (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정
KR1020207000732A Active KR102659791B1 (ko) 2017-07-06 2018-07-03 당단백질을 만들기 위한 세포 배양 과정

Country Status (13)

Country Link
US (5) US20190010531A1 (enExample)
EP (2) EP3967765A1 (enExample)
JP (5) JP7265494B2 (enExample)
KR (4) KR102782655B1 (enExample)
CN (3) CN110914293B (enExample)
AU (4) AU2018298039B2 (enExample)
BR (1) BR112020000127A2 (enExample)
CA (1) CA3067847A1 (enExample)
IL (1) IL271524A (enExample)
MX (2) MX2020000228A (enExample)
SG (1) SG11201912548XA (enExample)
TW (2) TW202526028A (enExample)
WO (1) WO2019010191A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN113679744B (zh) * 2020-05-18 2023-12-29 中国人民解放军军事科学院军事医学研究院 寨卡病毒或其与用于免疫检查点治疗的药物在治疗胶质母细胞瘤中的用途
CN114058673A (zh) * 2021-09-15 2022-02-18 江苏先思达生物科技有限公司 一种脂肪肝检测试剂及其在脂肪肝检测中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501749A (ja) 2014-01-13 2017-01-19 アムジエン・インコーポレーテツド 組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DE60309238T2 (de) 2002-03-08 2007-06-06 Asml Netherlands B.V. Lithographische Maske, lithographischer Apparat und Verfahren zur Herstellung einer Vorrichtung
KR100897379B1 (ko) 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
WO2006047380A2 (en) * 2004-10-22 2006-05-04 Amgen, Inc. Method and media for single cell serum-fee culture of cho cells
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US7642078B2 (en) * 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
KR101423344B1 (ko) * 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2008154014A2 (en) * 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
WO2011014838A1 (en) * 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
CN102115728B (zh) * 2009-12-31 2012-09-26 北京清大天一科技有限公司 无血清动物细胞培养基干粉、液体培养基及其制备方法
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
SG187885A1 (en) * 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
IN2014CN03072A (enExample) * 2011-10-31 2015-07-31 Merck Sharp & Dohme
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
BR112014031842B1 (pt) * 2012-06-21 2020-09-15 Baxalta GmbH Método para remover um contaminante viral de uma preparação
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
HK1206628A1 (en) * 2012-08-02 2016-01-15 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
JP6309521B2 (ja) 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
MX364591B (es) 2013-03-15 2019-05-02 Regeneron Pharma Antagonistas de il-33 y usos de estos.
US20160237400A1 (en) * 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
CA2908407C (en) * 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
KR102399005B1 (ko) 2014-03-11 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
TWI717319B (zh) 2014-05-27 2021-02-01 中央研究院 得自類桿菌屬之岩藻糖苷酶及其用途
EP3152318A1 (en) * 2014-06-03 2017-04-12 Lupin Limited Cell culture process for producing a protein
CN107001461A (zh) 2014-09-16 2017-08-01 瑞泽恩制药公司 抗胰高血糖素抗体及其使用方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
TW202140776A (zh) * 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501749A (ja) 2014-01-13 2017-01-19 アムジエン・インコーポレーテツド 組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節

Also Published As

Publication number Publication date
CN118878651A (zh) 2024-11-01
US20210388408A1 (en) 2021-12-16
AU2025203053A1 (en) 2025-05-22
JP2020526196A (ja) 2020-08-31
JP2023052471A (ja) 2023-04-11
EP3967765A1 (en) 2022-03-16
KR20240055885A (ko) 2024-04-29
EP3649144A4 (en) 2021-07-21
CN110914293A (zh) 2020-03-24
JP7736872B2 (ja) 2025-09-09
MX2024013233A (es) 2024-12-06
JP7265494B2 (ja) 2023-04-26
KR20210084695A (ko) 2021-07-07
US20190010531A1 (en) 2019-01-10
AU2018298039A1 (en) 2020-01-16
AU2023202659A1 (en) 2023-05-18
US20210388407A1 (en) 2021-12-16
JP7525672B2 (ja) 2024-07-30
JP2024138033A (ja) 2024-10-07
KR20200026248A (ko) 2020-03-10
CN110914293B (zh) 2024-08-13
MX2020000228A (es) 2020-08-10
AU2021229121A2 (en) 2021-10-14
IL271524A (en) 2020-02-27
CA3067847A1 (en) 2019-01-10
KR20250041082A (ko) 2025-03-25
TW202526028A (zh) 2025-07-01
WO2019010191A1 (en) 2019-01-10
CN114075269A (zh) 2022-02-22
AU2023202659B2 (en) 2025-01-30
TW201934570A (zh) 2019-09-01
US20200255880A1 (en) 2020-08-13
JP2021166537A (ja) 2021-10-21
US20200131554A1 (en) 2020-04-30
SG11201912548XA (en) 2020-01-30
BR112020000127A2 (pt) 2020-07-07
EP3649144A1 (en) 2020-05-13
KR102659791B1 (ko) 2024-04-23
AU2021229121A1 (en) 2021-09-30
JP2025172879A (ja) 2025-11-26
AU2018298039B2 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
JP7736872B2 (ja) 糖タンパク質を作製するための細胞培養方法
JP2024156901A (ja) 調節されたグリカンプロファイルを有する抗体
EA042958B1 (ru) Процесс культивирования клеток для получения гликопротеина
BR122024025107A2 (pt) Métodos para produzir um anticorpo glicosilado em um meio de cultura celular, e para produzir um meio de cultura celular
Roucka et al. Glycosylation Pattern of Biotechnologically Produced Proteins-Lectin Array Technology as a Versatile Tool for Screening?

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240417

Application number text: 1020207000732

Filing date: 20200109

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240503

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241213

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250312

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250312

End annual number: 3

Start annual number: 1

PG1601 Publication of registration